Abstract
Full text links
Read article at publisher's site: https://doi.org/10.1016/j.cell.2004.11.004
Read article for free, from open access legal sources, via Unpaywall: http://www.cell.com/article/S0092867404010463/pdf
References
Articles referenced by this article (56)
p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines.
Mol Cell Biol, (3):770-778 2000
MED: 10629033
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
Cancer Res, (23):7717-7722 1990
MED: 2253215
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
Oncogene, (9):1061-1068 1998
MED: 9764816
The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.
Gene, (1-2):15-30 2001
MED: 11602342
Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients.
Cell Death Differ, (3):246-251 2002
MED: 11859407
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
Science, (5170):346-355 1994
MED: 8023157
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
Cancer Res, (3):794-799 1994
MED: 8306343
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.
Proc Natl Acad Sci U S A, (5):2420-2424 1979
MED: 221923
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
Proc Natl Acad Sci U S A, (5):2948-2953 2002
MED: 11867759
p73 function is inhibited by tumor-derived p53 mutants in mammalian cells
Mol. Cell. Biol 1999
Show 10 more references (10 of 56)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Article citations
Targeting mutant p53: a key player in breast cancer pathogenesis and beyond.
Cell Commun Signal, 22(1):484, 10 Oct 2024
Cited by: 0 articles | PMID: 39390510 | PMCID: PMC11466041
Review Free full text in Europe PMC
The αvβ6 integrin specific virotherapy, Ad5<sub>NULL</sub>-A20.FCU1, selectively delivers potent "in-tumour" chemotherapy to pancreatic ductal adenocarcinoma.
Br J Cancer, 131(10):1694-1706, 05 Oct 2024
Cited by: 0 articles | PMID: 39369056 | PMCID: PMC11555051
MG53 suppresses tumor growth via transcriptional inhibition of KIF11 in pancreatic cancer.
Transl Oncol, 50:102118, 11 Sep 2024
Cited by: 0 articles | PMID: 39265509 | PMCID: PMC11416540
Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines.
Cell Rep, 43(8):114616, 09 Aug 2024
Cited by: 0 articles | PMID: 39128004 | PMCID: PMC11372443
p53 at the crossroads of tumor immunity.
Nat Cancer, 5(7):983-995, 15 Jul 2024
Cited by: 1 article | PMID: 39009816
Review
Go to all (867) article citations
Data
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
Fukuoka Igaku Zasshi, 100(6):217-228, 01 Jun 2009
Cited by: 13 articles | PMID: 19670804
Review
Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Oncogene, 20(33):4441-4449, 01 Jul 2001
Cited by: 40 articles | PMID: 11494139
The differential effects of mutant p53 alleles on advanced murine lung cancer.
Cancer Res, 65(22):10280-10288, 01 Nov 2005
Cited by: 396 articles | PMID: 16288016